Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
KCNJ6 antisense RNA 1 (KCNJ6-AS1), also known as KCNJ6-IT1, is a long non-coding antisense RNA transcribed from the genomic region opposite to the KCNJ6 gene[1][4]. As an antisense RNA, KCNJ6-AS1 is part of a group of non-coding transcripts that can regulate the expression of their associated sense gene—often by mechanisms such as transcriptional interference, chromatin modification, or modulation of mRNA stability[2][6]. No direct evidence is currently available linking KCNJ6-AS1 to a specific physiological or disease role, nor is it established as a therapeutic target. However, by analogy to other antisense lncRNAs, it may be implicated in fine-tuning KCNJ6 gene expression or participating in epigenetic processes[2]. No drugs are known to interact specifically with KCNJ6-AS1, and it should not be confused with the protein-coding KCNJ6 gene, which is important for potassium ion channel function[1][5][7].
Target of antisense oligonucleotides (ASOs, class-wide mechanism for antisense RNAs)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on KCNJ6 antisense RNA 1 (KCNJ6-AS1).